Terms: = Lymphoma AND NCOR2, SMRTE-tau, 9612, ENSG00000196498, SMRTE, TNRC14, TRAC-1, SMRT, CTG26, TRAC1 AND Prognosis
2 results:
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
Ma G; Gao Y; Jing X; He C; Liu H; Wu X; Gao Z; Li Y; Zhang S; Zhao G
Leuk Lymphoma; 2023 Jan; 64(1):140-150. PubMed ID: 36215154
[TBL] [Abstract] [Full Text] [Related]
